REPL - Replimune Group, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Woburn,
United States
Type: Equity
REPL price evolution
REPL
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.31 | $77.63 | $108.12 | |
| Short term investments | $368.68 | $420.76 | $432.62 | |
| Net receivables | $4.29 | $3.71 | $3.45 | |
| Inventory | ||||
| Total current assets | $479.16 | $508.18 | $550.04 | |
| Long term investments | ||||
| Property, plant & equipment | $52.13 | $51.78 | $51.81 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $53.77 | $54.22 | $53.85 | |
| Total investments | $368.68 | $420.76 | $432.62 | |
| Total assets | $532.93 | $562.4 | $603.89 | |
| Current liabilities | ||||
| Accounts payable | $3.9 | $4.37 | $4.88 | |
| Deferred revenue | ||||
| Short long term debt | $3.86 | $3.82 | $3.8 | |
| Total current liabilities | $38.65 | $39.83 | $32.24 | |
| Long term debt | $71.95 | $56.92 | $57.04 | |
| Total noncurrent liabilities | $72.74 | $57.39 | $57.62 | |
| Total debt | $75.81 | $60.74 | $60.84 | |
| Total liabilities | $111.39 | $97.23 | $89.86 | |
| Shareholders' equity | ||||
| Retained earnings | -$646.21 | -$595.09 | -$535.04 | |
| Other shareholder equity | $4.73 | $5.49 | $3.97 | |
| Total shareholder equity | $421.54 | $465.17 | $514.03 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $148.23 | $107.58 | $184.15 | $61.14 |
| Short term investments | $436.8 | $289.71 | $293.78 | $109.06 |
| Net receivables | $2.94 | $3.06 | $2.95 | $2.96 |
| Inventory | ||||
| Total current assets | $592.6 | $403.98 | $483.75 | $174.25 |
| Long term investments | ||||
| Property, plant & equipment | $52.35 | $55.58 | $57.72 | $58.21 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $53.99 | $57.22 | $59.35 | $59.85 |
| Total investments | $436.8 | $289.71 | $293.78 | $109.06 |
| Total assets | $646.59 | $461.19 | $543.1 | $234.1 |
| Current liabilities | ||||
| Accounts payable | $5.36 | $3.73 | $2.35 | $3.43 |
| Deferred revenue | ||||
| Short long term debt | $3.76 | $3.63 | $3.46 | $3.28 |
| Total current liabilities | $33.83 | $20.76 | $14.55 | $11.87 |
| Long term debt | $57 | $29.21 | $29.82 | $38.51 |
| Total noncurrent liabilities | $57.47 | $29.21 | $29.82 | $38.51 |
| Total debt | $60.76 | $32.84 | $33.28 | $41.79 |
| Total liabilities | $91.3 | $49.96 | $44.37 | $50.38 |
| Shareholders' equity | ||||
| Retained earnings | -$485.49 | -$311.2 | -$193.17 | -$112.3 |
| Other shareholder equity | $5.73 | -$0.97 | -$0.39 | -$0.98 |
| Total shareholder equity | $555.29 | $411.23 | $498.73 | $183.72 |
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $42.85 | $49.1 | $40.44 | |
| Selling, general & administrative | $13.69 | $14.73 | $15.21 | |
| Total operating expenses | $56.54 | $63.83 | $55.65 | |
| Operating income | -$56.54 | -$63.83 | -$55.65 | |
| Income from continuing operations | ||||
| EBIT | -$49.09 | -$58.75 | -$47.7 | |
| Income tax expense | $0.47 | -$0.2 | $0.2 | |
| Interest expense | $1.55 | $1.5 | $1.66 | |
| Net income | ||||
| Net income | -$51.12 | -$60.04 | -$49.55 | |
| Income (for common shares) | -$51.12 | -$60.04 | -$49.55 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $126.53 | $79.55 | $56.75 | $38.76 |
| Selling, general & administrative | $50.55 | $38.77 | $23.2 | $17.44 |
| Total operating expenses | $177.08 | $118.31 | $79.95 | $56.2 |
| Operating income | -$177.08 | -$118.31 | -$79.95 | -$56.2 |
| Income from continuing operations | ||||
| EBIT | -$169.84 | -$115.81 | -$77.81 | -$50.71 |
| Income tax expense | $0.29 | |||
| Interest expense | $4.16 | $2.22 | $3.06 | $1.92 |
| Net income | ||||
| Net income | -$174.28 | -$118.04 | -$80.87 | -$52.63 |
| Income (for common shares) | -$174.28 | -$118.04 | -$80.87 | -$52.63 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$51.12 | -$60.04 | -$49.55 | -$49.24 |
| Operating activities | ||||
| Depreciation | $0.68 | $0.65 | $0.62 | $0.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $8.24 | $9.12 | $8.85 | $6.92 |
| Total cash flows from operations | -$47.12 | -$43.59 | -$48.59 | -$32.8 |
| Investing activities | ||||
| Capital expenditures | -$1.72 | -$1.75 | -$0.45 | -$0.25 |
| Investments | $55.67 | $14.44 | $7.81 | -$22.5 |
| Total cash flows from investing | $53.96 | $12.68 | $7.36 | -$22.75 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0 | $0.55 | $1.21 | $0.03 |
| Net borrowings | $14.87 | -$0.11 | -$0.1 | -$0.1 |
| Total cash flows from financing | $14.87 | $0.44 | $1.1 | -$0.08 |
| Effect of exchange rate | -$0.03 | -$0.02 | $0.01 | -$4.45 |
| Change in cash and equivalents | $21.68 | -$30.48 | -$40.11 | -$60.08 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$174.28 | -$118.04 | -$80.87 | -$52.63 |
| Operating activities | ||||
| Depreciation | $2.45 | $2.15 | $1.71 | $0.53 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $28.13 | $24.25 | $11.79 | $7.74 |
| Total cash flows from operations | -$128.05 | -$82.18 | -$61.39 | -$60.55 |
| Investing activities | ||||
| Capital expenditures | -$2.27 | -$2.34 | -$2.39 | -$6.54 |
| Investments | -$140.23 | $0.53 | -$186.38 | $1.31 |
| Total cash flows from investing | -$142.5 | -$1.81 | -$188.78 | -$5.23 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $283.51 | $6.86 | $383.5 | $90.58 |
| Net borrowings | $27.79 | -$0.26 | -$11.04 | $9.94 |
| Total cash flows from financing | $311.3 | $6.6 | $372.46 | $100.17 |
| Effect of exchange rate | -$0.11 | $0.82 | $0.72 | -$0.14 |
| Change in cash and equivalents | $40.64 | -$76.57 | $123.02 | $34.25 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.16 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |